HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutics that targets bioactive signaling lipids to treat human diseases. The company's drug development programs include Sphingomab, a humanized monoclonal antibody for the treatment of cancer, age-related macular degeneration, and heart failure; and Lpathomab, a monoclonal antibody, which works against lysophosphatidic acid, a bioactive lipid that promotes cancer-cell growth and metastasis in a range of tumor types.
Market Cap | 100.553 Million | Shares Outstanding | 25.784 Million | Avg 30-day Volume | 169.891 Thousand |
P/E Ratio | -3.2 | Dividend Yield | EPS | -1.24 | |
Price/Sales | 3.445 | Price cash flow ratio | Price free cash flow ratio | -5.6 | |
Book Value | 0.4 | Price to Tangible Book | -76.97 | Alpha | -0.02 |
Short Interest Ratio | % Short Interest to Float | R-squared | 0.111173 | ||
BETA | 2.16136 | 52-week High/Low | 5.15 / 1.24 | Stddev | 0.28524 |
Q3 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 0 | 2 | -100.0% | 0 (0.0%) | 1 (0.06%) | -100.0% |
Funds Holding: | 30 | 32 | -6.25% | 12 (0.79%) | 13 (0.84%) | -7.69% |
13F shares: | 11.135 Million | 8.869 Million | 25.55% | 8.421 Million | 6.356 Million | 32.5% |
% Ownership | 47.0306 | 37.4598 | 25.55% | 35.5691 | 26.844 | 32.5% |
New Positions: | 1 | 3 | -66.67% | |||
Increased Positions | 9 | 8 | 12.5% | 4 | 3 | 33.33% |
Closed Positions | 3 | 2 | 50.0% | 1 | 1 | 0.0% |
Reduced Positions | 6 | 9 | -33.33% | 3 | 4 | -25.0% |
Total Calls | 0 | 0 | ||||
Total Puts | 0 | 0 | ||||
PUT/CALL Ratio | ||||||
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
10.8 Thousand total shares from 2 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
CAVANAUGH STEFANIE L. CFO, TREASURER, SECRETARY |
|
81,879 | 2021-01-06 | 2 |
NEWTON TODD CHIEF EXECUTIVE OFFICER |
|
412,306 | 2021-01-05 | 2 |
|
1,700,900 | 2020-10-28 | 2 | |
|
3,109,512 | 2020-07-17 | 1 | |
|
3,109,512 | 2020-07-17 | 1 | |
|
3,302,674 | 2020-05-26 | 1 | |
PTV SPECIAL OPPORTUNITIES I, L.P. |
|
2,811,241 | 2020-05-26 | 1 |
SCHWARTZHOFF BRET VP, US SALES & MARKETING |
|
88,841 | 2020-05-07 | 1 |
|
21,137 | 2020-05-07 | 1 | |
GOSTOUT CHRISTOPHER J. CHIEF MEDICAL OFFICER |
|
67,327 | 2020-05-07 | 1 |
|
18,742 | 2020-05-07 | 1 | |
MOLESPHINI JOHN J EVP, OPERATIONS |
|
61,371 | 2020-05-07 | 1 |
|
17,909 | 2020-05-07 | 1 | |
|
15,970 | 2020-05-07 | 1 | |
|
1,329,512 | 2020-01-02 | 0 | |
|
1,580,518 | 2019-08-12 | 0 | |
|
11,367 | 2018-02-28 | 0 | |
|
4,202,140 | 2017-11-15 | 0 | |
PTV SPECIAL OPPORTUNITIES I, L.P. |
|
4,152,463 | 2017-11-15 | 1 |
MCWILLIAMS DENNIS L. PRESIDENT, CCO |
|
96,051 | 2017-09-15 | 0 |
|
5,243,372 | 2017-07-25 | 0 | |
|
No longer subject to file | 2017-07-24 | 0 | |
TRIBIE CHARLES EXEC VP OF OPS |
|
894 | 2017-05-25 | 0 |
|
No longer subject to file | 2016-12-29 | 0 | |
|
No longer subject to file | 2016-12-29 | 0 | |
|
No longer subject to file | 2016-12-29 | 0 | |
ATKINSON GARY J G CEO AND CFO |
|
No longer subject to file | 2016-12-29 | 0 |
|
No longer subject to file | 2016-12-29 | 0 | |
|
No longer subject to file | 2016-12-29 | 0 | |
|
0 | 2016-12-29 | 0 | |
|
0 | 2016-12-29 | 0 | |
|
0 | 2016-12-29 | 0 | |
|
0 | 2016-12-29 | 0 | |
|
0 | 2016-12-29 | 0 | |
|
0 | 2016-12-29 | 0 | |
WOODNUTT GARY CHIEF SCIENTIFIC OFFCER |
|
0 | 2016-02-16 | 0 |
PAGGIARINO DARIO A. CHIEF DEVELOPMENT OFFICER |
|
0 | 2016-02-16 | 0 |
LACK MICHAEL INTERIM CEO |
|
0 | 2014-11-03 | 0 |
|
2,780,836 | 2014-09-26 | 0 | |
PANCOAST SCOTT R PRESIDENT & CEO |
|
116,435 | 2014-08-19 | 0 |
SABBADINI ROGER ALLEN VP & CHIEF SCIENTIFIC OFFICER |
|
0 | 2012-03-14 | 0 |
|
No longer subject to file | 2011-01-03 | 0 | |
BENDER JOHN F SENIOR VP-RESEARCH & DEVELOP. |
|
0 | 2008-09-24 | 0 |
GARLAND WILLIAM A VP - DRUG DEVELOPMENT |
|
50,000 | 2008-09-22 | 0 |
|
12,105,311 | 2008-08-13 | 0 | |
HANSEN GENEVIEVE VICE PRESIDENT, RESEARCH |
|
0 | 2007-11-20 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-01-07 16:36:09 -0500 | 2021-01-06 | J | 218 | a | 81,879 | direct | ||||||||||
2021-01-07 16:36:28 -0500 | 2021-01-05 | J | 3,479 | a | 412,306 | direct | ||||||||||
GAGNON NEIL - > 10% Owner by self as trustee of gagnon securities llc profit sharing plan |
2020-12-17 18:49:52 -0500 | 2020-12-16 | S | 2,488 | $4.16 | a | 14,656 | indirect | ||||||||
2020-12-17 18:49:52 -0500 | 2020-12-16 | S | 8,314 | $4.16 | a | 351,043 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |